Celularity Inc.

NASDAQ:CELU

Biotechnology

Healthcare
$1.83 +138.53%

+$1.22 today

Market cap
$52.97M
Beta
0.54
P/E (TTM)
-0.6
EPS (TTM)
-$3.58
52W Low $0.56High $4.00

Volume 0.00M

Average 0.13M

CELU Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Celularity Inc.NASDAQ: CELU

Other Income / Expenses · Q4 FY2025 · quarter ended Dec 2025

Other income / expenses remains negative

Q4 FY2025 other income / expenses was -$2.3M, compared with -$4.01M a year earlier. Trailing-twelve-month other income / expenses was -$30.41M.

Context

  • Other income / expenses amounted to 114.5% of revenue in FY2025, up 78.5 pp from a year earlier.
  • Other income / expenses increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near -$2.3M or moves back toward the trailing-twelve-month quarterly average of -$7.6M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$2.3M+77.4% QoQ
Last fiscal yearDec 2025
-$30.41M-55.7% YoY
LTMDec 2025
-$30.41M-55.7% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+42.7%——
1 year-55.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(30.41M) USD
Year-over-year change
-55.7%

Other Income / Expenses vs competitors

How CELU compares with its peers on the latest reported figures

  • CELU's LTM Dec 2025 other income / expenses of -$30.41M is the lowest of the 4 companies compared; the peer median is $501.25K.
  • Its year-over-year change of -55.7% is the 3rd highest of 4, against a peer median of -45.4%.
  • Other income / expenses amounts to 114.5% of revenue for CELU, versus a peer median of 5.0%.
CELU Competitors Peer median
Other Income / Expenses for CELU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$1.75M -45.4%+29.5%5.0%
ANVSAnnovis Bio, Inc.LTM Mar 2026$501.25K +112.9%+66.3%—
PYPDPolyPid Ltd.LTM Mar 2026-$17.55M -1078.4%——
CELUCelularity Inc.LTM Dec 2025-$30.41M -55.7%—114.5%
Peer median (excluding CELU) $501.25K-45.4%+47.9%5.0%

Competitors are the stored peer set for CELU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.34M17.98M22.77M54.22M26.55M
Cost of Revenue9.65M19.67M16.02M14.99M6.36M
Gross Profit11.68M(1.69M)6.76M39.23M20.19M
Gross Margin54.8%-9.4%29.7%72.4%76.0%
Research & Development88.35M78.36M30.47M17.39M15.03M
Selling, General & Admin71.34M66.02M50.58M58.64M51.27M
Operating Expenses120.74M23.91M199.04M77.59M81.5M
Depreciation & Amortization8.82M9.44M9.32M7.92M7.3M
EBITDA(88.11M)(138.83M)(183.95M)(43.71M)(77.66M)
EBITDA Margin-413.0%-772.4%-807.8%-80.6%-292.5%
Operating Income(109.06M)(25.6M)(192.29M)(38.36M)(61.31M)
Operating Margin-511.2%-142.4%-844.4%-70.7%-230.9%
Interest Income332K365K320K331K262K
Interest Expense3.17M03.02M6.26M6.75M
Other Income / Expenses8.96M39.81M(4M)(19.53M)(30.41M)
Income Before Tax(100.1M)14.21M(196.29M)(57.89M)(91.71M)
Pre-Tax Margin-469.2%79.0%-862.0%-106.8%-345.4%
Income Tax Expense20K13K10K03K
Net Income(100.12M)14.19M(196.3M)(57.89M)(91.8M)
Net Margin-469.3%79.0%-862.0%-106.8%-345.8%
EPS (Basic)(7.87)1.01(11.02)(2.64)(3.59)
EPS (Diluted)(7.87)0.95(11.02)(2.64)(3.59)
Weighted Avg Shares12.73M13.99M17.81M21.89M25.6M
Weighted Avg Shares (Diluted)12.73M14.98M17.81M21.89M25.6M

Celularity Inc.

NASDAQ:CELU

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.